Clinical Research Directory
Browse clinical research sites, groups, and studies.
Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies
Sponsor: BioCryst Pharmaceuticals
Summary
This is a phase 3b open-label study providing access to berotralstat for HAE patients who were previously enrolled in berotralstat studies.
Official title: An Open-label Study to Provide Berotralstat Access to Subjects With Type 1 and 2 Hereditary Angioedema Who Were Previously Enrolled in Berotralstat Studies
Key Details
Gender
All
Age Range
2 Years - Any
Study Type
INTERVENTIONAL
Enrollment
139
Start Date
2021-07-23
Completion Date
2031-08
Last Updated
2025-12-23
Healthy Volunteers
No
Conditions
Interventions
berotralstat
BCX7353 capsules or granules administered orally once daily
Locations (16)
Study Center
Ottawa, Canada
Study Center
Brno, Czechia
Study Center
Pilsen, Czechia
Study Center
Grenoble, France
Study Center
Marseille, France
Study Center
Paris, France
Study Center
Frankfurt, Germany
Study Center
Skopje, North Macedonia
Study Center
Krakow, Poland
Study Center
Martin, Slovakia
Study Center
Cape Town, South Africa
Study Center
Daegu, South Korea
Study Center
Gwangju, South Korea
Study Center
Seoul, South Korea
Study Center
Madrid, Spain
Study Center
Bristol, United Kingdom